Roquefort Therapeutics (LON:COIL) Receives “House Stock” Rating from Shore Capital Group

Shore Capital Group reissued their house stock rating on shares of Roquefort Therapeutics (LON:COIL) in a report published on Monday, Marketbeat Ratings reports.

Roquefort Therapeutics Trading Up 11.8%

COIL opened at GBX 8.50 on Monday. The stock has a 50-day moving average of GBX 9.17 and a 200 day moving average of GBX 9.40. The company has a current ratio of 0.63, a quick ratio of 3.07 and a debt-to-equity ratio of 8.18. Roquefort Therapeutics has a 12 month low of GBX 6.75 and a 12 month high of GBX 12.50. The firm has a market cap of £36.28 million, a P/E ratio of -0.39 and a beta of 0.05.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.